Chicago, IL - A nonrandomized trial of a new ventricular septal occluder designed specifically for the closure of defects that occur post-MI suggests that while mortality is still high following the ...

Within the last 24 months, I have financial relationship(s) or affiliation(s) with a manufacturer, marketer, reseller, or distributor of a healthcare product or service involved in the management of ...

Please provide your email address to receive an email when new articles are posted on . W.L. Gore and Associates announced its occluder device was approved by the FDA for percutaneous closure of ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

BOSTON--(BUSINESS WIRE)-- NMT Medical, Inc. (NASDAQ: NMTI), an advanced medical technology company that designs, develops, manufactures and markets proprietary implant technologies that allow ...

Atrial septal defect closure techniques have evolved considerably over recent decades. Traditional surgical repair, once the mainstay of treatment for congenital heart anomalies, has gradually been ...